For researchers comparing these two GHS-R1a agonists, the core question is straightforward: is maximum GH potency or maximum selectivity more important for the protocol at hand
In a multicenter, randomized, placebo-controlled dose-finding trial, cagrilintide at doses ranging from 0.3 to 4.5 mg weekly produced dose-dependent weight reductions, with the 4.5 mg dose achieving approximately 10.8% weight loss at 26 weeks compared to 3.0% with placebo
It stimulates both synthesis and breakdown of collagen in skin
While NAC differs from NAD+, it supports cellular energy indirectly by boosting glutathione production
Mounjaro produced the highest average weight loss in head-to-head injectable trials
In this episode of the Huberman Lab, choreographer Twyla Tharp discusses key aspects of the creative process, focusing on the need for discipline and physical preparedness